SCM
APRE icon

Stonepine Capital Management’s Aprea Therapeutics APRE Stock Holding History

Stonepine Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-102,242
Closed -$14.4K – 62
2025
Q1 		$14.4K Sell
102,242
-46,979
-31% -$147K 0.01% 65
2024
Q4 		$491K Buy
149,221
+12,047
+9% +$40.3K 0.4% 40
2024
Q3 		$377K Hold
137,174
– – 0.24% 34
2024
Q2 		$558K Buy
+137,174
New +$707K 0.51% 21

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Stonepine Capital Management's APRE Position: Q2 2025 in Review

Stonepine Capital Management sold out of Aprea Therapeutics (APRE) in Q2 2025, closing a stake of 102,242 shares — an estimated $14.4K sold.

Stonepine Capital Management first reported a position in APRE in Q2 2024 and held it in 4 quarters. The position peaked at $558K in Q2 2024. 23 funds tracked by Wall St. Rank hold APRE as of Q2 2025.

  • Stonepine Capital Management reported no remaining Aprea Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 102,242 Aprea Therapeutics shares in Q2 2025, an estimated $14.4K.
  • Stonepine Capital Management first reported a position in Aprea Therapeutics in Q2 2024 and held it in 4 quarters.
  • Stonepine Capital Management's Aprea Therapeutics position peaked at $558K in Q2 2024.
  • 23 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2025.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.